Best compounded tirzepatide telehealth in 2026

Medically reviewed by Dr. Jonathan Snipes, MD and Kim Callender, NP, FNP-BC. Last reviewed June 4, 2026.

The short answer

Six telehealth services prescribe compounded tirzepatide direct to patients today. RxPepsDirect has the lowest unit price ($45 per 12mg vial plus a one-time $39 visit) in 28 states. Henry Meds is the cheapest monthly all-inclusive bundle at $179/month flat across 41 states. Mochi Health at $278/month effective offers the most structured weight-loss programming but covers only about 10 states. Eden Health covers the widest geography (~50 states) and runs its own in-house compounding pharmacy (Contigo, acquired August 2025). Aspire Health and Nava Health round out the field with narrower state footprints and tirzepatide bundled into broader peptide programs. Branded Zepbound and Mounjaro prescribers (Ro, Calibrate, Form Health, etc.) are not on this list because they don’t dispense compounded.

How we built this comparison

We checked every site on May 15, 2026. To make the list, a service has to publish compounded tirzepatide on its public site (no account required) and bill cash-pay through a US 503A pharmacy. Branded tirzepatide (Zepbound, Mounjaro) is a different product and is not counted. Effective monthly cost reflects what the patient actually pays end-to-end: medical visit fee plus medication. Per-unit cost is the lowest published starter dose where available.

Side-by-side comparison

1. RxPepsDirect

Best for: the lowest cash price on a per-vial basis. $45 for a 12mg starter vial, $39 for the medical visit, pharmacy bills you at wholesale.

RxPepsDirect is a Denver, Colorado-based telehealth service that partners with Optimal Balance Pharmacy (Texas 503A). Tirzepatide comes in two formulations: Tirzepatide/B-12 from $45/12mg and Tirzepatide/Glycine from a higher starting price for patients who react to B-12. Both use the same active molecule as Zepbound and Mounjaro. Higher-dose titration vials are listed publicly with their own prices so patients can plan the cost as they titrate up.

RxPepsDirect is the only service on this list that doesn’t bundle. You pay $39 once for the medical visit; that’s it from the clinic. Optimal Balance bills you separately for the medication, at wholesale, with no clinic markup. There’s no subscription, no auto-refill, no membership tier.

• Starter price: $45 per 12mg vial (Tirzepatide/B-12); higher-dose titration vials priced separately
• Medical visit: $39 one-time per order
• States licensed: 32 (medical director: Dr. Jonathan Snipes, NPI 1821250077)
• Pharmacy: Optimal Balance Pharmacy (503A, Texas)
• Lab testing: Eagle Analytical (sterility via ScanRDI, endotoxin per USP <85>, potency per USP <621>)
• Carrier options: B-12 (cyanocobalamin) or glycine plus B-6

The trade-off: 30-state coverage is narrower than Eden (~50) or Henry Meds (41). If you live in AL, AK, AR, HI, LA, MS, MO, SC, or WV, Henry Meds is the next-cheapest option. Tirzepatide/B-12 product page or read how compounded tirzepatide compares to the branded versions.

2. Henry Meds

Best for: patients who want a flat monthly all-inclusive price and the broadest state coverage. $179/month covers medication, provider visits, supplies, and shipping.

Henry Meds is one of the largest compounded GLP-1 telehealth services in the US. The $179/month rate is flat (medication, visits, supplies, and shipping all included), which makes it the cheapest all-inclusive bundle on this list. Coverage is 41 states (not available in AL, AK, AR, HI, LA, MS, MO, SC, or WV).

Henry also publishes an oral tirzepatide tablet product at higher monthly prices for patients who want to avoid injections. The compounding pharmacy partner is not named on the public pricing page.

• Effective monthly cost: $179 flat for compounded injectable tirzepatide
• States licensed: 41 (excludes AL, AK, AR, HI, LA, MS, MO, SC, WV)
• Pharmacy: Partner 503A pharmacy (not named publicly)
• Bundle includes: medication, visits, supplies, shipping
• Oral option: tirzepatide tablets available at higher monthly prices

3. Mochi Health

Best for: patients who want structured weight-loss programming (dietitians, group support, lab tracking) bundled with the medication, and don’t mind paying a premium for it.

Mochi Health is GLP-1-first. The base membership is $79/month ($39 promotional first month), and compounded injectable tirzepatide adds $199/month, for an effective cost of $278/month. That’s the highest monthly price on this list, but it includes more programming: registered dietitians, lab review, structured weight-loss curriculum, and ongoing provider check-ins.

The trade-off is geography. Mochi serves about 10 states (Arizona, Colorado, Florida, Georgia, Illinois, Massachusetts, Maryland, Minnesota, New York, Oregon). The pharmacy partner is not named publicly.

• Effective monthly cost: $278 ($79 base plus $199 tirzepatide add-on)
• States licensed: ~10 (AZ, CO, FL, GA, IL, MA, MD, MN, NY, OR)
• Pharmacy: Partner 503A pharmacy (not named publicly)
• Bundle includes: medication, programming, dietitian access, lab review

4. Eden Health

Best for: the widest state coverage and a service that owns its own compounding pharmacy.

Eden Health is the largest service on this list by geographic reach (~50 states). In August 2025 the company acquired Contigo Compounding, a 503A pharmacy, which now operates as Eden’s in-house fulfillment. That vertical integration is real: it lets Eden offer micro-titration doses, faster turnaround on adjustments, and direct supply-chain control.

The trade-off is price transparency. Tirzepatide pricing on Eden is not visible until you complete an intake; subscription terms vary by program tier. If clear up-front pricing matters more than national coverage, RxPepsDirect or Henry Meds are a better fit. Detailed RxPepsDirect vs Eden comparison.

• Effective monthly cost: account-gated, varies by tier
• States licensed: ~50
• Pharmacy: Contigo Compounding (in-house, acquired August 2025)
• Bundle includes: medication, provider visits, member portal

5. Aspire Health

Best for: patients who want to combine tirzepatide with other peptides (BPC-157, CJC-1295/Ipamorelin, NAD+, tesamorelin) under one provider.

Aspire Health is a Nebraska-based telehealth service that prescribes both compounded tirzepatide and a small list of other peptides (BPC-157, CJC-1295/Ipamorelin, NAD+, Tesamorelin) in roughly 20 US states. For a patient running a weight-loss plus recovery protocol from a single clinician, Aspire is one of the few options where everything sits under one chart.

Pricing is not on the public site; the intake flow gates pricing behind a health assessment.

• Effective monthly cost: account-gated
• States licensed: ~20
• Pharmacy: partner 503A pharmacy (not named publicly)
• Bundle includes: tirzepatide plus 4 other peptides under one clinician

6. Nava Health

Best for: patients near the Virginia or Maryland clinics who want in-person visits as part of their tirzepatide program.

Nava Health prescribes tirzepatide and semaglutide alongside a broader peptide formulary (BPC-157, TB-500, sermorelin, tesamorelin, GHK-Cu, others). The brick-and-mortar clinics are in Ashburn (VA), Fairfax (VA), Bethesda (MD), and Columbia (MD); the telehealth arm extends to 15 states. Pricing is consultation-gated.

• Effective monthly cost: consultation-gated
• States licensed: 15
• Pharmacy: “accredited US compounding pharmacies” (not named)
• Bundle includes: tirzepatide plus 10 other peptides plus in-person visits where available

Why Ro, Hims, and Calibrate aren’t on this list

You’ll see these names searching for tirzepatide telehealth. They focus on branded GLP-1s (Zepbound, Mounjaro) rather than compounded tirzepatide, which is a different product and a different price tier. Mounjaro and Zepbound run $1,000+ per month cash-pay before insurance. If your insurance covers branded GLP-1s, services like Ro, Hims, Calibrate, Form Health, Hone Health, Sesame Care, and PlushCare may be cheaper than compounded; if your insurance won’t cover them, compounded is usually the cheaper path. Each company’s current offering changes quickly, so verify against their live site if you’re choosing between branded and compounded.

Clinical efficacy and benefits

Liver Fibrosis and Metabolic Dysfunction-Associated Liver Disease

Tirzepatide demonstrates efficacy in improving liver fibrosis in patients with metabolic dysfunction-associated liver disease (MASLD), a common comorbidity in obesity. A 2026 systematic review and network meta-analysis evaluated pharmacotherapies for MASLD patients with fibrosis stages F1 through F3 and found tirzepatide among the effective interventions for reducing fibrosis progression.^[7]

MASLD, formerly known as nonalcoholic fatty liver disease (NAFLD), affects approximately 25 to 30% of adults in the United States, with higher prevalence in individuals with obesity and type 2 diabetes. Liver fibrosis represents the pathological accumulation of scar tissue in the liver and is a key determinant of long-term outcomes in MASLD. Fibrosis stages range from F0 (no fibrosis) to F4 (cirrhosis), with F1 through F3 representing progressive scarring without cirrhosis.

The network meta-analysis compared multiple pharmacologic interventions across randomized controlled trials, assessing fibrosis improvement as a primary outcome. Tirzepatide's dual GLP-1 and GIP receptor agonism appears to confer metabolic benefits beyond glycemic control and weight loss, including improvements in hepatic fat content and inflammatory markers that contribute to fibrosis regression. These findings support tirzepatide as a therapeutic option for patients with obesity-related liver disease, though dedicated prospective trials with biopsy-confirmed endpoints remain important for definitive guidance.

Clinicians prescribing tirzepatide for weight management should consider baseline liver health assessment in appropriate patients, particularly those with elevated liver enzymes or imaging findings suggestive of hepatic steatosis. The reduction in liver fibrosis represents an additional cardiometabolic benefit that may inform treatment selection in patients with multiple obesity-related comorbidities.

How to choose between them

Three questions narrow it down fast:

1. How important is the lowest unit price? If cost is the deciding factor, RxPepsDirect ($45 starter vial plus $39 visit) and Henry Meds ($179/month all-inclusive) are the two cheapest paths. RxPepsDirect is cheaper per vial; Henry Meds is cheaper if you want everything bundled into one flat charge.
2. How important is state coverage? Eden Health covers ~50 states, Henry Meds 41, RxPepsDirect 28. If you live in AL, AK, AR, HI, LA, MS, MO, SC, or WV (states where Henry Meds doesn’t serve and RxPepsDirect may not yet), Eden Health is usually the answer.
3. Do you want bundled programming? Mochi’s $278/month includes a dietitian, group support, and structured curriculum. If you want medication only and no programming, RxPepsDirect or Henry Meds give you that for less.

Bottom line

For pure unit price on compounded tirzepatide, RxPepsDirect is the cheapest at $45 per 12mg vial plus a one-time $39 visit, billed through Optimal Balance Pharmacy at wholesale. For an all-inclusive monthly bundle, Henry Meds at $179/month is the next-cheapest and covers more states. Mochi Health is the most expensive but bundles the most programming. Eden Health has the widest geography and an in-house pharmacy. Aspire and Nava are useful if you want tirzepatide combined with a broader peptide protocol. Branded Zepbound and Mounjaro prescribers are a different category entirely and run many times the cash-pay price.

See RxPepsDirect tirzepatide pricing or start a $39 visit.

Clinical Evidence

The tirzepatide molecule in every compounded formulation on this list is the same 39-amino acid dual GIP/GLP-1 receptor agonist tested in the phase 3 SURPASS trials and approved by the FDA under the brand names Mounjaro (type 2 diabetes) and Zepbound (obesity). The active ingredient is identical; the difference is the carrier (B-12, glycine, or B-6) and the dispensing pathway (503A compounding pharmacy versus branded manufacturer).

SURPASS Phase 3 Efficacy

The SURPASS clinical trial program enrolled over 10,000 patients with type 2 diabetes. At 40 weeks, tirzepatide 5mg once weekly reduced HbA1c by 1.87 to 2.07 percentage points versus placebo, and 10mg and 15mg doses achieved reductions of 2.0 to 2.5 percentage points. Weight loss at the same time point ranged from 7 to 12kg depending on dose. These results established tirzepatide as the most potent glycemic agent in the GLP-1 class and led to FDA approval of Mounjaro in May 2022 and Zepbound in November 2023.

Two-Year Outcomes in Early Type 2 Diabetes

A 2026 randomized controlled trial published in Annals of Internal Medicine compared tirzepatide to intensified conventional care in patients with early type 2 diabetes over 24 months. Patients receiving tirzepatide demonstrated superior glycemic control compared to those receiving intensified conventional therapy with multiple oral agents and insulin titration. The tirzepatide group also achieved significantly greater weight reduction at two years. These findings extend the evidence base for tirzepatide beyond the original phase 3 SURPASS trials, demonstrating durability of effect in a real-world comparator setting. The study enrolled patients within three years of type 2 diabetes diagnosis, a population that may benefit from early intensive pharmacologic intervention to preserve beta-cell function and delay microvascular complications.^[1]

Safety considerations and monitoring

Compounded tirzepatide carries the same active-ingredient safety profile as branded Mounjaro and Zepbound. The most common adverse events are gastrointestinal (nausea, diarrhea, constipation, vomiting), are usually mild to moderate, and ease over the first four to eight weeks of dose escalation. A few specific risks and drug interactions warrant closer attention, and RxPepsDirect prescribers screen for each of them during the intake consultation.

Thyroid safety and screening

The FDA-approved prescribing information for tirzepatide carries a boxed warning for thyroid C-cell tumors, based on dose-dependent tumors seen in rodent studies. It is unknown whether tirzepatide causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans. Tirzepatide is contraindicated in patients with a personal or family history of MTC and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Before prescribing compounded tirzepatide, RxPepsDirect clinicians (Dr. Jonathan Snipes, MD and Kim Callender, FNP-BC) screen for personal or family history of MTC and MEN 2; patients with these conditions are not candidates for therapy.

A 2026 retrospective analysis in Clinical Obesity followed 527 patients through 12 months of tirzepatide and found that 5.3% developed or had progression of a thyroid condition, most often nodular/goitre disease or drug-induced thyroiditis. Baseline thyroid disease and end-stage renal disease were the significant risk factors, leading the authors to recommend periodic thyroid testing for those higher-risk patients.^[2]Patients with a history of Hashimoto's or other thyroid disease should tell their prescriber so monitoring can be arranged.

Lithium interaction

Patients maintained on lithium for bipolar disorder or other psychiatric conditions need extra caution. A 2026 case report in the Journal of Clinical Psychopharmacology documented severe lithium toxicity requiring hemodialysis in a previously stable bipolar I patient after starting tirzepatide; the mechanism is thought to involve reduced fluid intake and altered renal lithium clearance.^[3] Anyone taking lithium or another mood stabilizer should have lithium levels checked before starting tirzepatide and monitored during dose escalation, in coordination with their prescribing psychiatrist. RxPepsDirect prescribers review every current medication at intake, so tell your provider before starting therapy.

Peripheral arterial disease and limb outcomes

For patients with peripheral arterial disease (PAD), the real-world evidence is reassuring. A 2026 systematic review and meta-analysis in Diabetes Research and Clinical Practice pooled six studies covering more than 240,000 patients and found GLP-1-based therapies associated with significant reductions in major adverse limb events (HR 0.59, 95% CI 0.39-0.90) and major adverse cardiovascular events (HR 0.67, 95% CI 0.53-0.85), with the most consistent benefit in patients with diabetes.^[4]Because these are observational data, they show association rather than proof of cause. Patients with PAD or significant cardiovascular disease are evaluated individually at intake and may need additional monitoring.

Body composition and quality of life

Tirzepatide's benefits extend past the number on the scale. A post-hoc analysis of the SURMOUNT-1 trial in the Journal of Endocrinological Investigation tracked waist-to-height ratio (WHtR), a marker of central adiposity and cardiometabolic risk. At 72 weeks, 54.7% of participants on tirzepatide 10 or 15 mg improved their WHtR category, versus 9.6% on placebo, and 16.7% reached a WHtR at or below 0.49.^[5]

Real-world quality-of-life data are more modest. A 2026 analysis of the U.S. Adelphi Real World Obesity programme in Advances in Therapy found that patients on tirzepatide reported somewhat less impairment on several health-survey and work-productivity measures than those on no obesity medication, though the differences between treatment groups were small.^[6]As an observational study, it describes associations rather than establishing that tirzepatide caused the difference.

References

1. Del Prato S, Heine RJ, Pérez Manghi FC, et al. Tirzepatide Versus Intensified Conventional Care After 2 Years of Treatment in Early Type 2 Diabetes: A Randomized Clinical Trial (SURPASS-EARLY). Ann Intern Med. 2026. PMID 42184419.
2. Manueli Laos EG, Serafica B, Fontaine-Nicola A, et al. Impact of Tirzepatide Therapy on Thyroid Disease: Understanding Risks and Emerging Insights. Clin Obes. 2026;16(3):e70084. PMID 42145153.
3. Patarroyo-Rodriguez L, Leung J, Philbrick K, et al. Tirzepatide-Associated Lithium Toxicity Necessitating Hemodialysis in Previously Stable Bipolar I Disorder. J Clin Psychopharmacol. 2026. PMID 42227267.
4. Boccatonda A, D'Ardes D, Brighenti A, et al. GLP-1-based therapies and limb outcomes in PAD: a systematic review and meta-analysis of real-world studies. Diabetes Res Clin Pract. 2026;236:113271. PMID 42009258.
5. Sattar N, Tchang BG, Vincent RP, et al. Shifts in waist-to-height ratio categories within tirzepatide groups: a post-hoc analysis of SURMOUNT-1. J Endocrinol Invest. 2026;49(6):1237-1243. PMID 42082865.
6. Gibble TH, Leith A, Harrison L, et al. Health-Related Quality of Life and Work-Related Outcomes in People with Obesity or Overweight Treated with Tirzepatide or Other Obesity Medications: United States Results from the Adelphi Real World Obesity Disease Specific Programme. Adv Ther. 2026;43(6):2704-2721. PMID 41965443.
7. Sun XY, Jiang HL, Ma YT, et al. Efficacy of pharmacotherapies in improving liver fibrosis among patients with MASLD and fibrosis stages of F1-F3: systematic review and network meta-analysis. J Transl Med. 2026;24(1):604. PMID 42192439.